ThreatNG Security Offers Free Access to Their Groundbreaking Security Platform for Organizations to Assess Cloud and SaaS Vulnerabilities
28.2.2023 17:00:00 EET | Business Wire | Press release
ThreatNG, a cybersecurity company dedicated to empowering organizations of all sizes to manage their external attack surface and digital risks, has announced the release of its agentless Cloud and SaaS Exposure Assessment Module. The company also announced free access to organizations to this groundbreaking platform to assess their external risk for a limited time.
The ThreatNG “Cloud and SaaS Exposure” Module supports the following vendors and technology categories:
- Amazon Web Services (AWS)
- Microsoft Azure
- Google Cloud Platform (GCP)
- Analytics
- Business Intelligence (BI)
- Customer Relationship Management (CRM)
- File Sharing
- Human Resources
- Security
- Video Telephony
ThreatNG continues to redefine External Attack Surface Management (EASM), Digital Risk Protection, and Security Ratings by announcing the availability of its Agentless Cloud and SaaS Exposure Assessment Module. Requiring only a domain and organization name, ThreatNG users can perform Outside-In Discovery, Assessment, Reporting, and Monitoring of their Cloud and SaaS Footprint, uncover Exposed Open Cloud Buckets, bring to light Unsanctioned Implementations (Shadow IT), and call to attention Brand Impersonations (Cybersquats) without using agents, credentials, API connections, browser plugins, and any other means that require prior knowledge.
ThreatNG further empowers its users by providing a differentiated, unmatched, and holistic approach by extending discovery and assessment of all Internet-exposed online applications, repositories, APIs, platform-as-a-service (PaaS), infrastructure-as-a-service (IaaS), and vendor technologies interconnected with Cloud and SaaS implementations.
“As more critical data and functions are migrating to the cloud, it becomes much more important for organizations to have visibility of all their digital assets exposed to the public and address all potential risks and threats. Our Cloud and SaaS Exposure module empower users with a proactive outside-in perspective,” said Eric Gonzales, founder of ThreatNG. “We are so confident in our technology’s capability that we are willing to provide organizations of all sizes with a free discovery and risk assessment of their Cloud and SaaS environments.”
To learn more about ThreatNG and its Cloud and SaaS Exposure Assessment capabilities, visit the company’s website, www.threatngsecurity.com/cloudexposure.
Cloud and SaaS Environments are continuously evolving. With new instances appearing, this constant change makes it challenging to keep an accurate inventory of sanctioned implementations and maintain good cyber hygiene overall. This growing Cloud and SaaS sprawl feeds into the ever-increasing problem of Shadow IT (Unsanctioned Implementations) and Cybersquats (Brand Impersonations). This uncontrollable sprawl has also led to increased security risks and exposures, a growth in phishing attacks abusing SaaS platforms, and cloud assets compromised more than on-premise assets (Verizon 2022 Data Breach Investigations Report).
Cloud and SaaS Impersonations (Cybersquats) and Exposed Data within Open Cloud Buckets are growing problems with organizations of all sizes and their Third Parties. Still, they are out of scope within most External Attack Surface Management (EASM), Digital Risk Protection, and Security Rating Services. ThreatNG unites these solution capabilities and empowers users to seamlessly bring Cloud and SaaS into the fold of Asset Inventory, Security & Governance, Subsidiary Security Monitoring, Third-Party Security Assessments, and Brand Protection through their innovative external discovery and assessment requiring only a domain and organization name.
Support for all of the above is available today and accompanied by all of the following investigation modules provided to all ThreatNG users:
- Domain Intelligence
- Technology Stack
- Sensitive Code Exposure
- Online Sharing Exposure
- Search Engine Exploitation
- Sentiment and Financials
- Archived Web Pages
- Social Media
- Dark Web
Contact ThreatNG Security today for a Free 30-Day Evaluation of their Cloud and SaaS Exposure Assessment Module.
About ThreatNG
ThreatNG is redefining external attack surface management (EASM), digital risk protection, and security ratings with a platform of unmatched breadth, depth, and capabilities in managing technical and business threats across the dark, deep, and open web. Living up to the company mantra (“Security Centric; Not Exclusive”), ThreatNG provides a configurable solution to target, discover, and assess digital assets across a definable ecosystem of organizations, subsidiaries, partners, third parties, supply chains, and customers. Bolstered and maintained by the open source intelligence (OSINT) experts at DarcSight Labs, ThreatNG empowers organizations of all types and sizes to uncover, understand, and manage their external digital threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005863/en/
Contact information
Erin Price
Email: erin@threatngsecurity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom